Bristol-Myers Squibb (NY:BMY)

61.55 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

95 96 Next >

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026 ↗

September 25, 2025

Via Stocktwits

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

September 25, 2025

From Bristol Myers Squibb

Via Business Wire

The Smartest Dividend Stock to Buy With $1,000 Right Now ↗

September 24, 2025

Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Announces Positive Outcomes From Multiple Myeloma Late-Stage Study ↗

September 23, 2025

Via Stocktwits

J&J’s Investigational Plaque Psoriasis Drug Outperforms Bristol Myers’ Sotyktu In Study ↗

September 17, 2025

Via Stocktwits

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

September 24, 2025

Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients ↗

September 23, 2025

Bristol Myers Squibb reported positive Phase 3 results for iberdomide in multiple myeloma; analysts eye CELMoDs as key to future growth.

Via Benzinga

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

September 23, 2025

From Bristol Myers Squibb

Via Business Wire

1 Reason to Buy Bristol Myers Squibb Stock ↗

September 23, 2025

Find out why investors seeking passive income want shares of this dividend payer in their portfolio.

Via The Motley Fool

Topics Intellectual Property

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...

Via MarketMinute

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

September 19, 2025

From Bristol Myers Squibb

Via Business Wire

Why Replimune Stock Plummeted by Almost 40% Today ↗

September 18, 2025

The fate of a once-promising cancer treatment now looks uncertain at best.

Via The Motley Fool

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

September 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗

September 17, 2025

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

Via Benzinga

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

Via Investor Brand Network

Topics Artificial Intelligence Intellectual Property

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb Announces Dividend

September 17, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

September 16, 2025

From Bristol Myers Squibb

Via Business Wire

3 Great High-Yield Dividend Stocks to Buy in September ↗

September 16, 2025

Quality yields above 6% from three very different market sectors.

Via The Motley Fool

BRISTOL-MYERS SQUIBB CO (NYSE:BMY): A High-Yield Dividend Stock with Strong Profitability ↗

September 15, 2025

Bristol-Myers Squibb (BMY) offers a compelling 5.22% dividend yield with a strong history of growth, backed by high profitability and an attractive valuation.

Via Chartmill

The Specter of Stagflation: A Looming Threat to Global Markets

September 10, 2025

The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high...

Via MarketMinute

Topics Artificial Intelligence Bonds ETFs

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Via Benzinga

Topics ETFs Government

The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now ↗

September 09, 2025

With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward.

Via The Motley Fool

Topics Intellectual Property

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy ↗

September 08, 2025

BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates.

Via Benzinga

S&P 500 Soars to Uncharted Territory: Is the Market Overvalued or Justified by a New Era of Growth?

September 04, 2025

The S&P 500 index has repeatedly scaled new all-time highs in recent months, a testament to robust corporate earnings and an enduring wave of optimism, largely fueled by advancements in Artificial...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields ↗

September 04, 2025

Via Benzinga

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗

September 04, 2025

Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results.

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

95 96 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.